Objective: Intratympanic steroids are increasingly used in the treatment of inner ear disorders, especially in patients with sudden sensorineural hearing loss (SNHL) who have failed systemic therapy. We reviewed our experience with intratympanic steroids in the treatment of patients with sudden SNHL to determine overall success, morbidity, and prognostic factors. Hypothesis: Intratympanic steroids have minimal morbidity and the potential to have a positive effect on hearing recovery in patients with sudden SNHL who have failed systemic therapy. Study Design: The authors conducted a retrospective review. Methods: Patients presenting with sudden SNHL defined as a rapid decline in hearing over 3 days or less affecting 3 or more frequencies by 30 dB or greater who underwent intratympanic steroids therapy (24 mg/mL dexamethasone) were reviewed. Excluded were patients with Meniere disease, retrocochlear disease, autoimmune HL, trauma, fluctuating HL, radiation-induced HL, noise-induced HL, or any other identifiable etiology for sudden HL. Patients who showed signs of fluctuation of hearing after injection were excluded. Pretreatment and posttreatment audiometric evaluations including puretone average (PTA) and speech reception threshold (SRT) were analyzed. Patient variables as they related to recovery were studied and included patient age, time to onset of therapy, status of the contralateral ear, presence of diabetes, severity of HL, and presence of associated symptoms (tinnitus, vertigo). A 20-dB gain in PTA or a 20% improvement in SDS was considered significant. Results: Forty patients fit the criteria for inclusion in the study. The mean age of the patients was 54.8 years with a range from 17 to 84 years of age. Overall, 40% (n ‫؍‬ 16) showed any improvement in PTA or SDS. Fourteen (35%) men and 26 (65%) women were included. Using the criteria of 20-dB improvement in PTA or 20% improvement in SDS for success, 27.5% (n ‫؍‬ 11) showed improvement. The mean number of days from onset of symptoms to intratympanic therapy was 40 days with a range of 7 days to 310 days. A statistically significant difference was noted in those patients who received earlier injection (P ‫؍‬ .0008, rank sum test). No patient receiving intratympanic dexamethasone after 36 days recovered hearing using 20-dB PTA decrease or a 20% increase in discrimination as criteria for recovery. Twelve percent (n ‫؍‬ 5) of patients in the study had diabetes with 20% recovering after intratympanic dexamethasone (not significantly different from nondiabetics at 28.6%, Fisher exact test, P ‫؍‬ 1.0). Comparison to other studies that used differing steroid type, concentration, dosing schedule, inclusion criteria, and criteria for success revealed, in many instances, a similar overall recovery rate. Conclusions: Difficulty in proving efficacy of a single modality is present in all studies on SNHL secondary to multiple treatment protocols, variable rates of recovery, and a high rate of spontaneous recovery. Forty percent of patients showed some improvement in SDS or PTA after treatment failure. When criteria of 20-dB PTA or 20% is considered to define improvement, the recovery rate was 27.5%. Modest improvement is seen with the current protocol of a single intratympanic steroid injec- 
INTRODUCTION
Idiopathic sudden sensorineural hearing loss (SNHL) is defined as a decline in hearing over 3 days or less affecting 3 or more frequencies by 30 dB or greater with no identifiable etiology. 1 Sudden SNHL affects between 5 and 20 persons per 100,000 year or approximately 4,000 new cases annually in the United States. 2 The HL is nearly always unilateral and is commonly associated with tinnitus and aural fullness. The true incidence of sudden SNHL is probably underestimated because many who recover hearing early (within the first few days) are unlikely to seek medical therapy.
Although this disorder is not one of the more common etiologies for HL, disproportionate interest in sudden SNHL exists most likely because it is one of the few reversible (sensorineural) hearing losses encountered by clinicians. 3 Another potential reason for high interest level is that sudden SNHL is encountered by all otolaryngologists in all areas of the country and treated as a true emergency often without the timeframe to allow for tertiary referral.
The etiology, natural history, and treatment of this disorder have been subjects of debate for many years. The actual number of patients recovering spontaneously from sudden SNHL without having sought medical attention is not known. The high rate of spontaneous recovery, up to 65%, 4 also confounds reviews as to the therapeutic efficacy of any single agent or therapeutic intervention. Any proposed therapeutic intervention must improve on the 65% recovery rate that would be seen if no intervention was offered. The treatment of patients with sudden SNHL remains varied among otologic centers with no standard protocol universally accepted. With no specific etiology, and a short timeline for effective therapy realized, a technique termed "shotgun" therapy is often used. This therapy entails multiple therapeutic agents geared toward the hypothetical etiologies given at once, because the narrow therapeutic window prevents trials with each agent singly. This commonly used technique prevents the determination of which, if any, of the agents were effective in restoring hearing. Notwithstanding the timeframe in which maximum recovery may occur, from several days 5, 6 to possibly several months, 7, 8 also leads to errors in determining treatment efficacy versus natural history. Despite high reported spontaneous recovery rates, it is our experience, and that of others, that hearing recovery is poor in those patients who have failed systemic therapy. 5, 9, 10 Multiple treatment protocols and agents have been proposed to treat SNHL. Steroids, antiviral agents, anticoagulants, vasodilators, antiinflammatory agents, and others have been proposed as therapeutic agents to treat sudden SNHL, most of which propose some benefit in the treatment of sudden SNHL. The most accepted current treatment of sudden SNHL is systemic steroids. Although proven to be effective in randomized, double-blind, placebo-controlled trials, 1, 11 other studies have questioned the efficacy of systemic steroids in the treatment of sudden SNHL. 2, 4, 8 Both short-term and long-term complications from systemic steroids are well known to otolaryngologists, leading to the continued investigation into directed therapy for inner ear disorders, including sudden SNHL. Intratympanic steroids offer the potential for directed therapy of a high concentration to the inner ear with avoidance of systemic side effects. Like most proposed therapies, the efficacy of intratympanic steroid therapy in the treatment of sudden HL has yet to be determined, although several reports have demonstrated efficacy especially after treatment failures. 9, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [25] [26] [27] 
Intratympanic Therapy
Itoh was the first to report on the use of intratympanic steroids for inner ear disease when he treated patients for Meniere disease in 1991. 22 The first report on the use of intratympanic steroids for sudden SNHL was by Silverstein in 1996. 12 Other authors have also described the use of intratympanic steroids in the treatment of sudden SNHL. 9, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [23] [24] [25] [26] [27] Although the efficacy has not been definitively proven, intratympanic steroids as a therapeutic option for sudden HL is increasingly used in the United States. The variability that exists in treatment protocols for sudden SNHL also applies to protocols that involve intratympanic steroids. The use of intratympanic steroids has evolved into 3 main protocols for treatment of sudden SNHL:
• As an initial or primary treatment for sudden SNHL without systemic steroids; • As adjunctive treatment given concomitantly with systemic steroids for sudden SNHL; and • As "salvage therapy" after failure of systemic steroids for sudden SNHL.
The primary reason for the use of intratympanic steroids without systemic steroids is in patients who cannot tolerate systemic steroids or those at greater risk for complications from systemic steroids (e.g., diabetics). 13, 15, 16 The majority of the literature concerning the use of intra-tympanic steroids in the treatment of sudden SNHL has reported the experience in treatment after failure of systemic therapy. 9, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [25] [26] [27] Two studies, however, have studied the effects of intratympanic steroids as a primary or first-line agent for patients with sudden SNHL 23, 24 used adjunctively with systemic steroids.
There are several advantages of intratympanic steroids as a treatment for sudden SNHL (Table I) . The procedure is well tolerated and relatively easy to perform. As an office-based procedure done under local (topical) anesthesia, there is an avoidance of general anesthesia. Most patients understand the concept of intratympanic injection and readily accept the proposed therapy. Unlike systemic therapies, intratympanic therapy allows for the selection of the affected ear to be treated. In addition to glucose intolerance and avascular necrosis of the hip, other less severe side effects of systemic steroids such as insomnia, irritability, gastritis, and mood changes may potentially be avoided with topical therapy. The primary disadvantage of intratympanic steroids is the lack of proven efficacy and/or superiority over systemic steroids. Other potential disadvantages include pain, tympanic membrane perforation, acute otitis media, otorrhea, vertigo, and the potential for further HL.
Described techniques for steroid perfusion of the middle ear for sudden SNHL differ in many aspects, including the type of steroid used. Dexamethasone is the most common steroid used for intratympanic use 14,15,18 -21,24,25 followed by methylprednisolone. 9, 13, 15, 16, 17, 23, 26, 27 Reports in the literature also differ in the strength of the solution (2-4 mg/mL 14, 20 to 25 mg/mL dexamethasone 15 ; 32 mg/ mL 23 to 62.5 mg/mL methylprednisolone). 9, 16, 17 The amount injected into the middle ear in most studies is between 0.3 and 0.5 mL, the approximate volume of the middle ear space. Techniques also differ in method of delivery: transtympanic needle injection, 9,13,15,19,20,17,24 -27 delivery through a myringotomy, 13, 14 delivery through a myringotomy with a tube, 12, 23 delivery with a wick placed in a myringotomy (Micromedics, Eagan, MN), 18, 21 and delivery through an implantable pump (Round Window m-Cath; Durect Corp., Cupertino, CA) to deliver the steroid as a constant infusion. 16, 17, 21 The length of time and number of injections in which patients are treated with intratympanic steroids also differs ranging from a single day to weekly transtympanic injections 9, 12, 14, 15, 18, 20, 23 to multiple weeks with selfadministered steroid drops 18, 21 to transtympanic injections given several times per week 19, 23, 25, 26 or to an implantable pump. 16, 17, 21 Reported complications are rare and include pain, 13 vertigo, 13, 16, 17, 20, 21 otitis media, 13 tympanic membrane perforation, 9,21 acne, 20 dysgeusia, 21 chronic otitis media, 21 and further HL. 16, 21 This study was undertaken to review the experience with 24 mg/mL intratympanic dexamethasone given at a single time point in the treatment of patients with idiopathic sudden SNHL that have failed systemic steroid therapy. Special attention was given to evaluating the safety of the procedure and correlation with improvement in hearing related to age, time to onset of therapy, prior therapy, diabetes, severity of loss, and status of the opposite ear.
MATERIALS AND METHODS

Inclusion Criteria
A retrospective review of the patients undergoing intratympanic steroid injection from January 1, 2000, to July 30, 2005, were reviewed, yielding 312 procedures in 195 patients (Table II) . These records were further reviewed to determine which patients underwent intratympanic steroid therapy for sudden SNHL. Ex- cluded from this group were those patients who did not meet the inclusion criteria outlined in Table I , patients with incorrect coding, incomplete records, inadequate follow up, or inadequate audiometric analysis. Patients undergoing multiple injections or patients receiving dexamethasone at any dose other than 24 mg/mL were excluded. All patients with fluctuating HL or Meniere disease were excluded. Eighty-five patients underwent intratympanic steroids for sudden SNHL for diagnoses other than Meniere disease. Excluded from this group were patients with fluctuating HL (8) head trauma (3), autoimmune HL (3), radiation-induced HL (1), noise trauma (1) barotrauma (1), labyrinthitis (1), congenital HL (1), delayed perilymph fistula after stapedectomy (1), and herpes zoster oticus (1). These exclusions left 64 patients with idiopathic sudden SNHL who underwent intratympanic dexamethasone perfusion and available for study. Six patients had had inadequate audiometric data, 4 patients failed to follow up, 4 patients had intratympanic steroids started concomitantly with oral steroids, and 2 had HL less than 30 dB and were excluded. Seven patients did not receive systemic steroids (diabetes, n ϭ 4; or refused, n ϭ 3) and were excluded. One patient failed a 5-day course of steroids and was injected on the fifth day and was excluded. Forty patients were available to study with idiopathic sudden SNHL who failed systemic therapy and underwent intratympanic dexamethasone as salvage therapy after at least 7 days of therapy.
We also present a control group of patients who failed systemic therapy, did not receive intratympanic therapy, and had at least one follow-up audiogram after determining failure of systemic steroids. Excluded from this group were patients who had Meniere disease, autoimmune HL, or any other identifiable hearing cause for HL. Any patient with fluctuating HL before steroid therapy was excluded.
Audiometric Data
Patients were all evaluated using standardized methods for pure-tone threshold audiometry and speech intelligibility by certified audiologists pre-and postinjection (Grason-Stadler GSI model 16 or 61). Pure-tone average (PTA) was calculated as an average of the threshold measured at 0.5, 1.0, and 2.0 KHz. Speech intelligibility (SDS) was tested by calculating the percent correct of a phonetically balanced, monosyllabic word list (Northwestern University, NU-6).
Technique
The correct ear is confirmed for injection by patient response and audiometric review. EMLA cream (AstraZeneca, Wilmington DE) is used for anesthesia by topical application. The EMLA cream is left on the tympanic membrane for 30 to 45 minutes. The cream is removed and the head is placed in position 45°toward the unaffected ear. The dexamethasone solution of 24 mg/mL (Table III) is checked and warmed to body temperature before injection. Before each procedure, the patient is counseled regarding the risks and expectations of the procedure and informed consent obtained. Approximately 0.3 to 0.5 mL of the solution is injected into the middle ear. No myringotomy, pressure-equalizing tube, or secondary myringotomy is made. No middle ear endoscopy is performed. On completion of the injection, the head is turned toward the affected side and then back away to the original position. This maneuver is performed in an attempt to maximize exposure of the solution in the middle ear space to the round window membrane. A second injection may be immediately performed if the first was felt to be inadequate or if inspection of the middle ear shows a predominantly air-filled middle ear space. Up to 3 injections may be given during this time period. The patient is asked to lie in the supine position with the head turned 45°away from the treated ear for 10 to 15 minutes on average. No subsequent injections are given on follow-up visits.
Statistical Analysis
Data are presented in numeric and percent form. Categorical data analysis was performed using 2 techniques or the Fisher exact test. Comparison between days before treatment and improvement was performed using the rank sum test. All statistical analysis used SigmaStat software 2.03 (SPSS Inc., Chicago, IL).
Reporting Recovery
The criteria used to define a successful recovery after therapy differs in the literature pertaining intratympanic steroids. A 20-dB improvement in PTA or a 20% improvement in discrimination was considered a successful therapeutic intervention. The data from this study were also applied to the criteria for success as defined in other studies that investigated the use of intratympanic steroids for sudden SNHL (see Table IV ). 
RESULTS
Patient Population
After inclusion and exclusion criteria were applied, 40 patients were available for study. There were 14 (35%) men and 26 (65%) women. The mean age was 54.8 with a range from 17 to 84 years of age. The mean age for the women was 58 years and for the men 48 years. The overall recovery rate for men was 35.7% and for women was 23% (P ϭ .5, Fisher exact test).
Overall Recovery. Forty patients fit the criteria for inclusion in the study. Overall, 40% (n ϭ 16) showed improvement in PTA or SDS. For those 37.5% (n ϭ 15) showing an improvement in PTA, the mean gain was 15 dB. For the 37.5% (n ϭ 15) showing an improvement in SDS, the mean gain was 31.9% (range, 8% to 88%). Using the criteria of 20-dB improvement in PTA or 20% improvement in SDS for success, a 27.5% (n ϭ 11) improvement was noted (Fig. 1 ). For these 27.5% who had an improvement, an average improvement in PTA of 16.9 dB (range, 0 -42 dB) and average improvement in SDS of 38.9% (range, 8% to 88%) was noted (Fig. 2 ). Seven patients (17.5%) showed worse PTA with a mean decrease of 3.8 dB (range, 2-7 dB). Five patients (12.5%) showed worse SDS after injection with a mean decrease of 16% (range, 8% to 28%). Thirty-five percent of patients had no change in hearing after intratympanic steroids.
Age Related to Recovery. Recovery as related to patient age was studied. Sixty-three percent of patients were under 60 years of age and had an overall recovery rate of 24%. Thirty-seven percent of patients were 60 years of age or older and had an overall recovery rate of 33.3% (P ϭ .7, Fisher exact test). Xenellis 27 2006 47% 10 dB PTA 15% (5% if treated after 2 days) †Study divided into two groups based on time to presentation. ‡Study involved only profound hearing loss; our data were adjusted accordingly. §Although response rates are similar, those that did respond in Parnes et al. had a significantly greater response than the current study. PTA ϭ pure-tone average; SDS ϭ speech discrimination score; Dex ϭ dexamethasone; MP ϭ methylprednisolone.
Prior Treatment. All patients entered had received systemic therapy before intratympanic injection. In addition to steroids, 85.4% received antiviral agents with a 28.9% recovery rate in this subset. Diuretics were used in 27.1% with a 23.1% recovery rate noted in this subset.
Recovery Related to Associated Symptoms. Vertigo was present in 37.5% of patients with a recovery rate of 20%. A total of 62.5% of patients did not have symptoms of vertigo and had an overall recovery of 32% (P ϭ .5, Fisher exact test). Tinnitus was present in 65% of patients with a 23.1% recovery in this group. Tinnitus was absent in 35% of patients with 36% showing recovery in this group (P ϭ .5, Fisher exact test).
Status of the Opposite Ear. A total of 87.5% of patients had normal hearing in the contralateral ear. The recovery rate in this group was 26.5%. Only 12.5% of patients had abnormal hearing in the contralateral ear. The recovery rate in this group with abnormal hearing in the contralateral ear was 33.3% (P ϭ 1.0, Fisher exact test).
Recovery Related to Time of Onset of Symptoms. The average number of days from onset of symptoms to intratympanic therapy was 40 days overall with a range of 7 days to 310 days. For the group (n ϭ 11) that responded to injection, the median was 14 days. For the group that did not respond, the mean was 31 days (P ϭ .008, rank sum test). No patient receiving intratympanic dexamethasone after 36 days recovered hearing using 20-dB PTA/ 20% discrimination as criteria for recovery. If patients receiving injections for sudden SNHL after 6 weeks are excluded, the recovery rate increases to 39.3% (Table V) .
Recovery Related to Severity of Loss. Recovery of hearing as related to severity of initial loss was studied. Twelve patients (30%) had HL greater than 90 dB with an 8.3% improvement rate noted in this group. Twenty-two patients (55%) had HL of 90 dB or less and greater than or equal to 50 dB with a 20% recovery rate noted in this group. Six patients (15%) had HL less than 50 dB and greater than 30 dB with an 33% improvement rate in this group (P ϭ . 2 2 ) (Fig. 3) . Patients with severe losses greater than 90 dB had a poorer recovery (8.3%) compared with losses that were less than or equal to 90 dB (35.7% recovery) (P ϭ .1, Fisher exact test).
Recovery Related to Diabetes. A total of 12.5% of patients in the study had diabetes. Twenty percent of those had recovery after intratympanic dexamethasone. The recovery rate in patients without diabetes was 28.6% (Fisher exact test, P ϭ 1.0). Four of the nine patients with diabetes did not receive systemic steroids and were not included in the primary study. The recovery rate was 25% (1 of 4) in this group.
Control Group. A matched group of patients who failed systemic steroid therapy were identified within the same time period as the study group. This group included 11 patients identified who had sudden SNHL, failed systemic steroid therapy, and were available for long-term follow up. Patients required pretreatment, posttreatment, and at least one more posttreatment audiogram after documentation of systemic steroid failure. There were 7 males and 4 females. The average age was 67 years with a range from 61 to 78 years. Average follow up from onset of symptoms was 271 days with a range from 22 days to 1,460 days. Recovery of hearing of 20-dB PTA or 20% SDS was seen in 9.1% of patients. Eighteen percent had a decline in hearing thresholds by 20 dB or 20% discrimination over time. The one patient who improved had no improvement in hearing with steroids at 2 weeks after onset of symptoms and treatment with steroids but had a 20% gain in SDS at 6 weeks follow up.
DISCUSSION
In a double-blind, placebo-controlled study, Wilson et al. showed a statistically significant benefit with systemic 
Effects of Steroids on Cochlear Function
Dexamethasone (9-fluro-11b,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione) is a synthetic corticosteroid used commonly in clinical medicine through oral, parenteral, and topical routes primarily for its antiinflammatory effect. The exact mechanism in which steroids may improve hearing is unknown. The effects of steroids are mediated through receptors found within the cytoplasm. Both glucocorticoid and mineralocorticoid receptors are found in the inner ear. 28 This study and others cited later suggest that steroids play a significant role in modulating cochlear function. Multiple studies have shown systemic steroids to have a positive effect on cochlear function. Other studies have shown steroids to decrease inflammation from labyrinthitis, 29 improve cochlear blood flow, 30 protect against cochlear ischemia, 31 protect against noiseinduced HL, 32 and regulate inner ear de novo protein synthesis. 33 Studies have shown the stria vascularis, which maintains Naϩ/Kϩ secretion necessary for maintenance of the endocochlear potential, to be a site for potential pathology in sudden HL. 34 Systemic steroids have also been shown to improve stria vascularis function and morphology 35 and therefore the potential to recover hearing after sudden SNHL.
Multiple studies have shown that intratympanic steroids are safe without evidence of histologic changes or cochlear dysfunction. 12,36 -39 Intratympanic steroids have been shown to increase cochlear blood flow, 12,36 prevent aminoglycoside toxicity, 40 prevent drill-induced noise loss, 37 and improve ion homeostasis necessary for cochlear function. 39 Intratympanic steroids were also shown to have a protective effect on stria vascularis changes after otitis media. 41 In a study of patients with tinnitus, intratympanic dexamethasone was found to have no adverse affect on cochlear function as measured by otoacoustic emission. 38 Other studies suggest that intratympanic steroids may not be beneficial in the treatment of HL. The potential for intratympanic steroids to cause decreased cochlear function has been suggested. 42 Intratympanic steroids have been shown to lead to round window inflammation. 43 Yang and colleagues noted that intratympanic steroids were ineffective at preventing immune-mediated labyrinthitis after induction of keyhole limpit hemocyanin (KLH) and therefore may be ineffective in treating sudden SNHL. 44 
Cochlear Pharmacokinetics
Steroids delivered intratympanically can achieve high concentrations in perilymph, higher than when administered by either intravenous or oral routes. 13, 45, 46 The pharmacokinetics of topically applied steroids within the cochlea have been studied. Using the markers trimethylphenylammonium (TMPA) 47 and horseradish peroxidase, 48 nonuniform distribution was noted with concentration of the markers near the round window (basal turn) higher than that of the apical turns. Salt found that substances can reach the vestibule through extracellular communication between the scalae across the spiral ligament as opposed to longitudinal flow through the helicotrema. 49, 50 These studies and that of Parnes 13 suggest nonlinear flow and interscalar communication of topically applied substances through the spiral ligament. 13, 49, 50 Using the data of Parnes 13 and Bachman, 46 Plontke, using the Washington University Cochlear Fluids Simulator model (the Washington University cochlear Fluids Simulator, a public domain program available online at http:// oto.wustl.edu/cochlea/), 47 studied the effects of single application and continuous delivery of intratympanic steroids on perilymph concentration. They found that relative distribution of drugs in the inner ear is unlikely to be affected by the application protocol. This finding is felt to be secondary to the clearance of the drug from the perilymph, i.e., a drug that is rapidly cleared will not progress along the scalar fluid. A steady state will be established within a matter of hours that will remain unchanged by further application. Application protocols did have a marked affect on drug levels achieved in the perilymph with continuous delivery resulting in higher perilymph levels than single application. 48 
Studies on Intratympanic Steroids for Sudden Sensorineural Hearing Loss
The first report of intratympanic steroids in the treatment of sudden SNHL was by Silverstein in 1996 12 followed by Parnes in 1999. 13 Several other reports have been published since this initial report, most since 2001 9,14 -21,23-27 (Table VI) . Most studies have shown the benefits of intratympanic steroids in the treatment of sudden HL in patients who had failed previous systemic therapy. Only 2 papers have studied the effects on intratympanic steroids as a primary or initial therapy used adjunctively with systemic steroids. 23, 24 Both of these studies reported that the addition of intratympanic steroids did not have a significant effect on the hearing recovery in sudden SNHL. Lauterman 23 compared patients who received intratympanic steroids with systemic steroids with patients who received no intratympanic steroids and found no benefit to the addition of intratympanic steroids in hearing recovery. Battista 24 noted minimal improvement after intratympanic steroids for sudden SNHL in his study of 25 patients all with profound (Ͼ90-dB PTA) HL. Silverstein, in a retrospective review of 46 patients treated with transtympanic steroids for a variety of disorders, had 8 patients with the diagnosis of sudden SNHL. One patient had improvement in speech reception thresholds from 110 dB to 85 dB and another from 75% to 65% SRT. 12 Parnes et al. treated 37 patients with a variety of inner ear disorders; 13 of these patients had sudden SNHL. Patients were treated with intratympanic methylprednisolone (9 patients) and intratympanic dexamethasone (4 patients). All patients presented within 6 weeks of onset of symptoms. Six of the 13 patients showed significant improvement in hearing thresholds, with 5 progressing from a severe or profound loss to relatively normal thresholds. No correlation between outcome and time of treatment after HL was noted. 13 Chandrasekhar treated 10 patients who had variety of inner ear disorders with 2 to 4 mg/mL dexamethasone intratympanically. The time interval between onset of loss and treatment averaged 33 days. Most patients had failed medical therapy; however, some were treated primarily. Overall improvement was noted with a mean improvement of 9-dB PTA and 15.8% discrimination. Improvement was noted in all patients with diabetes (3) and Meniere disease (2) . Patients with long intervals to treatment, downsloping audiogram, and surgical trauma to the inner ear did not show recovery with intratympanic steroids. 14 Lefebre and Staeker treated 6 patients with sudden SNHL with methylprednisolone infused with a microcatheter for 8 to 10 days. All patients had failed systemic therapy. All 6 patients showed improvement in hearing thresholds with an average of 16.25-to 25-dB improvement in thresholds. 16 Kopke et al. reported the results of intratympanic steroids delivered through an implanted microcatheter (62.4 mg/mL methylprednisolone at 10 L/ hour over 14 days) to treat patients with sudden SNHL. All of the patients treated in Kopke's study had failed a 2-week course of oral steroid therapy. Four of the 6 patients had sudden SNHL. Five of 6 patients treated within 6 weeks improved their hearing, with 4 returning to baseline hearing levels. None of the patients (3 of 3) who initiated treatment 6 weeks or more after the onset of the HL showed improvement. 17 Gianoli and Li in 2001 performed a prospective study on patients treated with intratympanic steroids (dexamethasone or methylprednisolone) after treatment failure with systemic steroids for a minimum of 1 week. A change of greater than or equal to 10 dB in the PTA or speech reception threshold or 10% in speech discrimination was considered a positive response. A 44% response rate was noted in these prior treatment failures with the average improvement of 15.2 dB and 21% SDS. 15 Silverstein et al. examined 19 patients with sudden SNHL treated with intratympanic dexamethasone delivered through a MicroWick for 2 to 4 weeks. Five (31%) patients had a positive response. The average gain in hearing was 45 dB and 39% discrimination. Patients treated earlier had better results, although 1 patient responded more than 1 year after the onset of symptoms. 18 Gouveris treated 40 patients with intratympanic steroids in a prospective study of patients who had failed systemic therapy. Overall significant improvements in hearing thresholds were noted. Reduced efficacy was noted in patients who had profound HL and primarily high frequency loss at presentation. 19 Lauterman et al. in 2005 reported the results of a prospective, controlled study in which transtympanic methylprednisolone was used as a primary treatment modality, not as salvage therapy after systemic steroids failure. Twenty-seven patients were treated with systemic therapy (rheologic agents and systemic steroids) with 13 of these undergoing intratympanic steroids in addition to the systemic therapy. No difference in recovery was noticed between the group treated with intratympanic steroids and the control group. Ho et al. in 2005 reported a randomized, controlled study of 39 patients with sudden SNHL in which 29 (74%) failed systemic steroids and were randomized into 2 treatment groups. Fifteen patients received intratympanic steroid therapy and 14 were continued on further medical therapy (without steroids). They noted 53% improvement in the intratympanic steroid group as opposed to 7.1% for the noninjected group using 30-dB gain in PTA as criteria for successful outcome. Age, treatment delay time, and sex did not affect response to therapy. 20 Herr and Marzo reported on 17 patients treated with transtympanic steroids (dexamethasone initially, methylprednisolone later in the study) through a MicroWick and/or round window catheter placement. All patients had failed prior systemic therapy with prednisone and were treated from 2 to 20 weeks after onset of HL. Overall, 53% showed improvement in thresholds after treatment. 21 The average improvement was 24.3 dB in those ears that showed improvement. Battista in 2005 enrolled 25 patients with profound SNHL. Both systemic and intratympanic steroids were used concomitantly. Overall poor results were achieved in this population of profound HL patients with only 12% (3 of 25) achieving a full or partial response. 24 Slattery et al. reported 20 patients treated with methylprednisolone for sudden SNHL that failed systemic steroids. Fifty-five percent showed clinically significant (10-dB PTA or 12% discrimination) improvement in hearing. Improvement in tinnitus was also noted. 9 In 2006, Dallan et al. treated 8 consecutive patients with intratympanic methylprednisolone in a prospective study, with 75% improving after a single injection. 26 Choung et al. had a 38% improvement following with intratympanic therapy compared to 6.1% improvement in a control group treated with systemic therapy alone. 25 Also in 2006 Xenellis showed a 47% improvement in patients with intratympanic therapy following treatment failure, while none of the patients in a matched control improved over time. 27 With the natural history of sudden SNHL suggesting a high recovery rate, it is difficult to determine if any therapeutic intervention actually improves hearing recovery. The natural history of untreated patients with sudden SNHL ranges from recovery rates of 31% to 65%. 1, 3, 4, 8 The range of hearing recovery reported in the literature in treated patients ranges from 35% to 89%. 7, 11 Several reasons may explain the significant differences in reported recovery rates between studies; however, the best explanation may lie in what is considered a "successful" treatment outcome. Mattox and Simmons reporting a relatively high spontaneous recovery rate of 65% classified good recovery as a final PTA of less than 40 dB or a more than 50-dB improvement in the initial audiogram. 4 Slattery et al. used the criteria described by Wilson et al. 1 to describe recovery (recovery of Ͼ50% of baseline hearing). Using this formula, they reported a hearing recovery rate with systemic therapy of 35%. Chen and Wilson using this formula described hearing recovery rates of 55% 3 and 78%, 1 respectively.
On review of the studies published to date in intratympanic steroids, it is clear that studies in the literature also differ on the definition of "success" for significant improvement after therapy. No definitive criteria exist to define recovery in patients with sudden SNHL, especially secondary recovery after initial treatment failure. The criteria to which the authors define recovery range from any improvement in PTA or SDS 14 to an improvement in 10-dB PTA or 10% SDS 15 to the criteria described by Wilson et al. 1 that describes recovery as Ͼ50% of the initial loss. 24 A true meta-analysis of the literature is not possible given the wide variance in treatment protocols, patient data, and reporting of data. However, if we apply our hearing outcome data to the criteria in the current literature, similar hearing recovery rates are often found. For example, Gianoli 15 reported a success rate of 44% using the criteria of 10-dB PTA/10% SDS; using this criteria applied to our data, the success rate rises from 26.7% to 40%. Table IV and Figure 4 illustrate the change in our reported success rate when different criteria are applied. Our hearing recovery rates are surprisingly similar to many other studies on intratympanic steroids for sudden SNHL when similar criteria are used to calculate the rates of improvement despite marked differences in treatment protocols, number of injections, steroid type and concentration. There are several possible explanations for the similar recovery rates between studies. One possible explanation is that the variables of steroid type, dose, and number of injections may have minimal influence on treatment outcome and recovery rates. Another possible explanation is that the injection had no effect at all and the similar recovery rates reflect the natural history of recovery from idiopathic sudden SNHL. Although possible in theory, the prognosis for recovery in patients with sudden HL who have failed systemic therapy in our experience and others is uniformly poor. 9, 10, 15 With the inclusion/exclusion criteria applied, all patients with Meniere disease, autoimmune HL, or fluctuating loss requiring multiple injections were excluded and only patients with true idiopathic sudden SNHL that failed systemic steroids were studied. Although our recovery rate is low (26.7%), it is difficult to compare with the reported natural history recovery rates, because our group had failed systemic therapy and were an average of 40 days out from onset of symptoms. The literature would support a low chance of further recovery in this group. In Ho's study, only 7.1% of the control group of those who failed systemic therapy gained further hearing on follow up. 20 Choung 25 and Xenellis 27 respectively showed 6.1% and 0% improvement in hearing after failed systemic therapy with long-term follow up. Zadeh noted an improvement in hearing for those patients seen and treated within 3 days of the onset of symptoms as compared with those treated beyond 3 days. 6 Shaia and Sheehy noted a significant improvement in patients treated within 1 week or less. However, some patients who initiated therapy after 3 months had recovery (10%). 52 Fuse et al. noted that the majority of patients who recovered completely after treatment with oral steroids did so within 7 to 10 days after administration of steroids. In long-term follow up of 3 months to 2 years, none of the patients with no recovery or partial recovery recovered to normal hearing levels. They noted that patients resistant to steroids with regard to early outcome continued to have poor hearing recovery during long-term follow up. 6 Ito et al. noted hearing outcomes in 90 patients treated for sudden HL. Patients with improvement within 2 weeks were more likely to have a better outcome. Patients with poor recovery at 2 weeks showed minimal improvement at 1-month follow up. 10 Lefebre reported that 100% of patients treated with steroids for sudden SNHL recovered within 7 days. 16 Because controversy exists regarding efficacy of systemic steroids in treating sudden SSNHL, it will exist as well regarding the use of intratympanic steroids in this treatment population. Truly, only one patient recovered hearing to within 10 dB of the contralateral ear with a second patient having a significant improvement in discrimination of the 40 treatment failures studied. These results are hardly considered dramatic. However, 39% of patients recovering 20 dB or 20% SDS (if treated within 6 weeks) in this group of treatment failures is higher than would be expected given our controls (9.1%), experience, and literature review. If we further exclude 7 patients treated with intratympanic steroids within 2 weeks of the onset of symptoms (i.e., study only those patients treated with intratympanic dexamethasone between 2 and 6 weeks after onset of symptoms), still, 26% improved by 20 dB or 20% SDS. This recovery is higher than what would be expected by our experience, control group (9.1%), and literature review. Although this represents one of the largest series of treatment failures to date treated with steroid perfusion, the statistical power of the study does not support efficacy. Although it lacks statistical power, the data suggest a trend toward efficacy of steroid perfusion in this treatment group.
We excluded patients who had Meniere disease, fluctuating HL, and autoimmune HL from the study to refine the study to patients with idiopathic sudden SNHL. Any patient whose hearing fluctuated and subsequently received multiple injections was excluded. This exclusion eliminated a number of patients who would have been classified as a good response. That is, some patients who responded to intratympanic injection whether recovery was from a true therapeutic intervention or from recovery through natural history were more likely to receive a second injection if hearing fluctuated. Those who did not respond to initial intratympanic steroids did not receive subsequent injections. Exclusion of all patients who demonstrated evidence of fluctuation of hearing before injection was done so improvement after injection would be less likely attributed to upward fluctuation; 87.5% of patients in the study group had a normal contralateral ear in the current study group, reflective of patients with idiopathic sudden SNHL.
Recovery in the group with diabetes (20%) was similar to the nondiabetics (28.6%). No complications were noted in this group; however, one patient did have worsening thresholds. Four of 9 (44%) of the patients with diabetes did not receive systemic steroids before injection with one (25%) recovering hearing using 20 dB or 20% discrimination as definition for recovery. These patients were not included in the primary study but are compared with those receiving systemic steroids in Figure 5 . Five of 9 (56%) received systemic steroids before injection with one (20%) showing recovery using this criteria. Chandrasekhar noted improvement in 3 of 3 patients with diabetes treated with intratympanic therapy for sudden SNHL. 14 Diabetic patients are felt to have a poorer overall recovery from sudden SNHL. 52, 53 Although not statistically significant, some of the differences between groups were noteworthy. Patients with abnormal hearing in the contralateral ear had a slightly better recovery rate (33%) than those with normal hearing in the contralateral ear (26.5%) (P ϭ 1.0, Fisher exact test). Patients with no vertigo had a recovery rate of 32% compared with those with vertigo who had a recovery rate of 20% (P ϭ .5, Fisher exact test). The presence of vertigo has been shown to be a poor prognostic sign in several studies. 2, 4, 21, 52, 53 Those patients with severe losses had a poorer recovery (8.3%) compared with losses that were less than 90 dB (35.7% recovery) (P ϭ .1, Fisher exact test). Severe losses have been shown in several studies to have poorer recovery rates. 2, 7, 11, 24 A total of 17.5% of patients (n ϭ 7) had a worse PTA (defined as any drop in the PTA on follow-up testing) after injection. Although this seems relatively high, the average drop in PTA was only 3.8 dB. A more significant drop was seen in changes in SDS. Only 5 patients had worsening of SDS (defined as any drop in SDS on follow-up testing) after injection, but the average drop was 16%. The majority of the loss is from one patient who dropped 28% on the SDS scores after injection. This patient developed a temporary perforation with otorrhea. If this patient is excluded, the average drop in discrimination in the remaining 4 patients is 12%. No other patient had perforation, otitis media, otorrhea pain, or vertigo after intratympanic injection. It is unclear as to whether these losses can be directly attributed to the procedure. Progression of loss may be seen in up to 15% of patients with sudden SNHL, 4 which is consistent with our controls (18%). These losses most likely fall within the range of natural progression of disease. No other complications were noted.
The limitations of this study lie primarily in the retrospective analysis of patient data. This study lacks formal control and should be interpreted as a description of the clinical experience from a single institution in the treatment of sudden SNHL with a single injection of intratympanic steroids. However, the studied group would be expected to have a poor prognosis given the delay to therapy (average over 40 days) and failure of systemic therapy. Our small control group is reflective of the fact that long-term follow up after documented treatment failure in patients is uncommon. Given the low numbers of our control population, statistical analysis was not possible; only descriptive analysis can be made in comparison to our treatment group. Other limitations may be the type of steroid used and the dosing schedule applied. Dexamethasone has good round window diffusion; however, the profile may not be as beneficial as methylprednisolone. Parnes showed that methylprednisolone had a higher concentration and longer duration in perilymph after transtympanic administration than hydrocortisone or dexamethasone. 13 Despite the practicality in treating patients with a single intratympanic injection of steroids, this protocol may not be as optimal as a continuous infusion or multiple injections. 16, 17 CONCLUSION Dramatic improvements in PTA or SDS were uncommon in this group of patients treated as salvage patients (failed systemic therapy), with only 1 patient in 40 recovering to within 10 dB of the contralateral ear. However, 39% of patients recovering 20 dB or 20% SDS (if treated within 6 weeks) in this group of treatment failures is higher than would be expected given our controls (9.1%), experience, and literature review. Although this represents one of the largest series of treatment failures to date treated with steroid perfusion, the statistical power of the study does not support efficacy. Despite failure to reach statistical significance, the data suggest a trend toward efficacy of steroid perfusion in patients who have failed systemic steroid therapy. No patient showed benefit based on our criteria from intratympanic steroids after 36 days when using this protocol for idiopathic sudden SNHL. A National Institutes of Health-sponsored, prospective trial is being conducted to determine the potential therapeutic efficacy in treating sudden SNHL, and will hopefully further answer questions regarding this treatment option.
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